Search results for " Ly"

showing 10 items of 2487 documents

Caecal leiomyoma detected by whole-body MRI in a patient with Hodgkin lymphoma: first case report

2017

Introduction. Hodgkin Lymphoma (HL) is one of the most curable malignant diseases. Modern treatments, like the combined radiochemotherapy and stem cell transplantation, have increased the number of malignant disease survivors. However, HL survivors are at risk of long-term effects, including the development of solid tumors. Secondary neoplasms are a major cause of late morbidity and mortality following treatment for HL. Case report. We report the case of a male patient, treated for HL by chemotherapy, who developed a large leiomyoma of the cecum one year after the treatment. A whole-body Magnetic Resonance (WBMRI) scan performed during the follow-up allowed the detection of this incidental …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentCecal NeoplasmsLaparoscopic surgeryBenign tumorLesionBiopsymedicineHumansWhole Body ImagingCaecal leiomyomaIncidental FindingsChemotherapyCaecal leiomyoma; Hodgkin lymphoma; Laparoscopic surgery; Magnetic resonance imaging; SurgeryLeiomyomamedicine.diagnostic_testbusiness.industryNeoplasms Second PrimaryMagnetic resonance imagingmedicine.diseaseHodgkin DiseaseMagnetic Resonance ImagingTransplantationSettore MED/18 - Chirurgia GeneraleLeiomyomaSurgeryOriginal ArticleRadiologyDifferential diagnosismedicine.symptomSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray ComputedbusinessHodgkin lymphomaGiornale di Chirurgia - Journal of Surgery
researchProduct

Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.

2005

: Background: Splenic marginal zone lymphoma (SMZL) is an infrequent B-cell neoplasm that pursues an indolent course. Signs and symptoms, mostly related to hypersplenism, are successfully managed by splenectomy. However, the therapy of patients who are not fit for a surgical procedure or who relapse after splenectomy, is still an unsettled issue. Patients and methods: We report a phase-II study on 16 patients with SMZL, three therapy naive and 13 pretreated, all showing systemic symptoms or progressive worsening of peripheral cytopenia, who were treated with pentostatin at a dose of 4 mg/m2 every other week for 6–10 wk. In relapsed patients, the median interval between diagnosis and treatme…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentSplenectomyPurine analogueDrug Administration SchedulemedicinePentostatinHumansProgression-free survivalSplenic marginal zone lymphomaLymphocytesAgedCytopeniaDeoxycoformycinbusiness.industrySplenic NeoplasmsRemission InductionNeoplasms Second PrimaryHematologyGeneral MedicineLymphoma B-Cell Marginal ZoneMiddle Agedmedicine.diseaseSMZLSurvival AnalysisSurgerysplenic marginal zonelymphomaDeoxycoformycinFemaleSplenic LymphomabusinessPentostatinvillous lymphocytesmedicine.drugEuropean journal of haematology
researchProduct

Immunologic effects of rituximab on the human spleen in immune thrombocytopenia

2011

Abstract Immune thrombocytopenia (ITP) is an autoimmune disease with a complex pathogenesis. As in many B cell–related autoimmune diseases, rituximab (RTX) has been shown to increase platelet counts in some ITP patients. From an immunologic standpoint, the mode of action of RTX and the reasons underlying its limited efficacy have yet to be elucidated. Because splenectomy is a cornerstone treatment of ITP, the immune effect of RTX on this major secondary lymphoid organ was investigated in 18 spleens removed from ITP patients who were treated or not with RTX. Spleens from ITP individuals had follicular hyperplasia consistent with secondary follicles. RTX therapy resulted in complete B-cell de…

AdultMalemedicine.medical_treatmentImmunologySplenectomySpleenT-Lymphocytes RegulatoryBiochemistryAntibodies Monoclonal Murine-DerivedImmune systemimmune system diseaseshemic and lymphatic diseasesHumansImmunologic FactorsMedicineImmunobiologyAgedAutoimmune diseaseB-LymphocytesPurpura Thrombocytopenic Idiopathicbiologybusiness.industryCell BiologyHematologyMiddle AgedTh1 Cellsmedicine.diseaseLymphatic systemmedicine.anatomical_structureImmunologyMonoclonalbiology.proteinFemaleRituximabAntibodyRituximabbusinessSpleenmedicine.drugBlood
researchProduct

Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Ita…

2018

Objective.Macrophage activation syndrome (MAS) is a reactive form of hemophagocytic lymphohistiocytosis, which can complicate adult-onset Still disease (AOSD). We investigated AOSD clinical features at the time of diagnosis, to assess predictors of MAS occurrence. Further, we analyzed the outcomes of patients with AOSD who experience MAS.Methods.Patients with AOSD admitted to any Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale center were retrospectively analyzed for features typical of AOSD, MAS occurrence, and their survival rate.Results.Of 119 patients with AOSD, 17 experienced MAS (12 at admission and 5 during followup). Twelve patients with MAS at first admission diff…

AdultMalemusculoskeletal diseases0301 basic medicineAdult onset still diseasemedicine.medical_specialtyAbdominal painMultivariate analysisSurvivalImmunologyStill DiseaseComorbidityGastroenterology03 medical and health sciences0302 clinical medicineRheumatologyInternal medicinePrevalencemedicineHumansImmunology and AllergySurvival rateRetrospective Studies030203 arthritis & rheumatologyFerritinHemophagocytic lymphohistiocytosisbiologybusiness.industryIncidencefungiMiddle AgedHyperferritinemic syndromemedicine.diseaseSurvival RateFerritin030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeFerritinsCohortbiology.proteinAdult onset still disease; Ferritin; Hyperferritinemic syndrome; Macrophage activation syndrome; Survival; Rheumatology; Immunology and Allergy; ImmunologyFemalemedicine.symptombusinessStill's Disease Adult-OnsetThe Journal of Rheumatology
researchProduct

HLA-B27-derived peptides as autoantigens for T lymphocytes in ankylosing spondylitis

1997

Objective.To study whether peptides derived from the HLA-B27 molecule sequence can stimulate peripheral blood T lymphocytes (PBL) from patients with HLA-B27-associated spondylarthropathies. Methods.PBL from 55 HLA-B27+ patients with ankylosing spondylitis (AS), 28 HLA-B27+ patients with other spondylarthropathies, 7 rheumatoid arthritis patients, and 30 HLA-B27+ and 22 HLA-B27- healthy controls were tested in lymphocyte proliferation assays with 4 synthetic peptides derived from the HLA-B*2705 molecule. Results. A 13-mer peptide (B27PA) induced significant proliferative responses in 17 of the 55 AS patients (stimulation index [SI] 2.5–17.5), as well as in 3 of the HLA-B27+ healthy controls …

AdultMalemusculoskeletal diseasesAdolescentT-LymphocytesT cellImmunologyEnzyme-Linked Immunosorbent AssayLymphocyte proliferationLymphocyte ActivationMajor histocompatibility complexAutoantigensCell LineInterferon-gammaRheumatologyAntigenHumansImmunology and AllergyMedicineSpondylitis AnkylosingPharmacology (medical)SpondylarthropathiesHLA-B27 AntigenAgedHLA-B27biologybusiness.industryT-cell receptorReceptors Antigen T-Cell gamma-deltaT lymphocyteMiddle AgedFlow CytometryPhenotypemedicine.anatomical_structureImmunologybiology.proteinFemalePeptidesbusinessArthritis & Rheumatism
researchProduct

Wheat consumption leads to immune activation and symptom worsening in patients with familial mediterranean fever : a pilot randomized trial

2020

We have identified a clinical association between self-reported non-celiac wheat sensitivity (NCWS) and Familial Mediterranean Fever (FMF). Objectives: A) To determine whether a 2-week double-blind placebo-controlled (DBPC) cross-over wheat vs. rice challenge exacerbates the clinical manifestations of FMF

AdultMalenon-celiac wheat sensitivityCD14 lymphocytesLipopolysaccharide Receptors610 Medizinlcsh:TX341-641Wheat HypersensitivityMonocytesArticleDouble-Blind MethodAIDAI score610 Medical sciencesHumansTriticumCross-Over Studiesinterleukin-1betaTumor Necrosis Factor-alphaCD14 lymphocytefood and beveragesFamilial Mediterranean FeverDisease ProgressionFemaletumor necrosis factor-αlcsh:Nutrition. Foods and food supplyamylase trypsin inhibitor
researchProduct

The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma

2016

The prognostic value of sentinel lymph node micrometastases in invasive breast cancer patients is still widely debated. Even if, in the absence of unequivocal guidelines, the axillary lynphadenectomy is not still performed in the routine clinical care of these patients.We have retrospectively analyzed 746 patients with operable invasive breast cancer and clinically negative axillary lymph nodes. These patients underwent conservative surgery or total mastectomy with sentinel lymph node biopsy. Patients with micrometastases in the sentinel lymph node treated with axillary dissection has been checked and the involvement of the remaining lymph nodes analyzed. Patients with micrometastases in th…

AdultNeoplasms Hormone-DependentBiopsy Fine-NeedleBreast carcinomaBreast NeoplasmsHumansRadionuclide ImagingTechnetium Tc 99m Aggregated AlbuminMastectomyAgedRetrospective StudiesAged 80 and overSentinel Lymph Node BiopsyCarcinoma Ductal BreastMicrometaseMiddle AgedPrognosisCombined Modality TherapyCarcinoma LobularNeoplasm MicrometastasisLymphatic MetastasisBreast carcinoma; Micrometases; Sentinel lymph node; SurgeryAxillaLymph Node ExcisionFemaleSurgeryNeoplasm Recurrence LocalRadiopharmaceuticalsSentinel lymph node
researchProduct

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

2011

Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting. Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune…

AdultNephrologyrituximab; autoimmune diseasesmedicine.medical_specialtyHealth StatusImmunologyDrug ResistanceAutoimmune DiseasesDrug HypersensitivityAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineRheumatologyimmune system diseaseshemic and lymphatic diseasesGermanyInternal medicinemedicineHumansImmunology and Allergyddc:610RegistriesRetrospective Studies030203 arthritis & rheumatologyAutoimmune diseasebusiness.industryRetrospective cohort studymedicine.diseaseRheumatology3. Good healthLymphomaPemphigusTreatment OutcomePatient SatisfactionAntirheumatic AgentsRheumatoid arthritisImmunologyRituximabRituximabbusinessImmunosuppressive Agents030217 neurology & neurosurgeryResearch ArticleFollow-Up Studiesmedicine.drugArthritis Research & Therapy
researchProduct

Application of a predictive model of axillary lymph node status in patients with sentinel node metastasis from breast cancer. A retrospective cohort …

2016

Abstract Background and objectives The Axillary Lymph Node Dissection (ALND) is the standard treatment in patients with invasive breast cancer and sentinel node metastasis, but in 60% of the cases there is no further axillary neoplastic involvement, so this invasive intervention represents an overtreatment. The purpose of the study is to identify patients with low risk of additional nodal metastases, to omit ALND. Methods The MSKCC Additional nodal metastasis nomogram was applied on a sample of 175 patients with invasive breast cancer who underwent ALND after detection of macrometastasis with the extemporaneous examination of the sentinel lymph node. Patients were classified as "low risk" w…

AdultOncologyAxilla; Breast neoplasms; Lymph node excision; Lymphatic metastasis; Sentinel lymph node biopsy; Surgerymedicine.medical_specialtySentinel lymph nodeBreast Neoplasms030230 surgeryRisk AssessmentSensitivity and SpecificityCohort Studies03 medical and health sciences0302 clinical medicineBreast cancerSentinel lymph node biopsyPositive predicative valueInternal medicinemedicineHumansMacrometastasisLymph nodeAgedRetrospective StudiesLymphatic metastasiAged 80 and overBreast neoplasmbusiness.industryAxillary Lymph Node DissectionGeneral MedicineMiddle AgedModels TheoreticalNomogramSentinel nodemedicine.diseaseNomogramsLymph node excisionmedicine.anatomical_structureROC CurveArea Under CurveLymphatic Metastasis030220 oncology & carcinogenesisAxillaFemaleSurgeryLymph NodesSentinel Lymph NodebusinessInternational Journal of Surgery
researchProduct

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Posit…

2015

Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (HER2) –positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant GeparSixto trial. Patients and Methods GeparSixto investigated the effect of adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response (pCR). A total of 580 tumors were evaluated before random assignment for stromal TILs and lymphocyte-predominant BC (LPBC). mRNA expression of immune-activating (CXCL9, …

AdultOncologyCancer Researchmedicine.medical_specialtyStromal cellReceptor ErbB-2medicine.medical_treatmentAntineoplastic AgentsTriple Negative Breast NeoplasmsCarboplatinchemistry.chemical_compoundLymphocytes Tumor-InfiltratingPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansAgedRandomized Controlled Trials as TopicChemotherapybusiness.industryTumor-infiltrating lymphocytesCancerFOXP3Middle AgedPrognosismedicine.diseaseNeoadjuvant TherapyCarboplatin3. Good healthCD8AGene Expression Regulation NeoplasticOncologychemistryChemotherapy AdjuvantCXCL9FemalebusinessJournal of Clinical Oncology
researchProduct